Clostridium Difficile

Feature Article

C difficile Treatment and Prevention: Novel Antibiotics and Immunologic Therapies

C difficile Treatment and Prevention: Novel Antibiotics and Immunologic Therapies

Experts review novel antibiotic therapies that may limit the impact on the gut microbiome, as well as passive immunization products that may bolster the immune response to C difficile toxins and possibly reduce the frequency of toxigenic strains.

Latest News

New Method Gauges Persistence of Donor Microbes After Fecal Transplant

New Method Gauges Persistence of Donor Microbes After Fecal Transplant

Therapeutic donor microbes can remain for months or years in patients who've undergone fecal microbiota transplantation.

Ridinilazole Beats Standard of Care in Phase 2 C difficile Study

Ridinilazole Beats Standard of Care in Phase 2 C difficile Study

Recurrent Clostridium difficile infection is associated with a significant economic and mortality burden, but new treatment shows promise.

Oral Prophylactic Therapy Designated Breakthrough Therapy for CDI Prevention

Oral Prophylactic Therapy Designated Breakthrough Therapy for CDI Prevention

The FDA granted Breakthrough Therapy designation to Synthetic Biologics' ribaxamase SYN-004 for Clostridium difficile infection prevention.

Community-based Risk Factors for C difficile Infection in Children

Community-based Risk Factors for C difficile Infection in Children

Community-associated C difficile infection in children was linked to the combination of commonly used antibiotics and exposure to the bacterium in the home and outpatient healthcare settings.

Asymptomatic Carriers of C difficile Increase Infection Risk in Others

Asymptomatic Carriers of C difficile Increase Infection Risk in Others

Asymptomatic carriers of Clostridium difficile in hospitals increase infection risk in other patients.

Gastric Acid Suppression Linked With Increased Risk of Recurrent CDI

Gastric Acid Suppression Linked With Increased Risk of Recurrent CDI

A meta-analysis study shows patients who take gastric acid suppressants have a higher risk for recurrent Clostridium difficile infection.

High Rate of Metronidazole Resistance Seen in C difficile Infection

High Rate of Metronidazole Resistance Seen in C difficile Infection

Antibiotic resistance to therapies for Clostridium difficile infection are common, and their patterns should be considered in algorithms designed to select therapies.

Lower Rates of Recurrent C difficile Infections With Bezlotoxumab

Lower Rates of Recurrent C difficile Infections With Bezlotoxumab

Bezlotoxumab was particularly effective in patients with risk factors for poor outcome, including older age, immunocompromise, and severe infection.

Restricting Fluoroquinolone Use Helped With CDI Decline in England

Restricting Fluoroquinolone Use Helped With CDI Decline in England

The outbreak of Clostridium difficile in England that began in 2006 was curbed by reducing the use of fluoroquinolones, according to a study.

Severe CDI Treatment With Vancomycin Has Lower 30-Day Mortality Risk

Severe CDI Treatment With Vancomycin Has Lower 30-Day Mortality Risk

No difference in the risk of Clostridium difficile infection (CDI) recurrence observed with vancomycin or metronidazole but 30-day mortality risk was significantly lower among patients with severe CDI treated with vancomycin.

Sign Up for Free e-newsletters